Verfahren zur Herstellung neuer Steroide

1,190,404. Steroid-17-lactones and -17- furans. AYERST, McKENNA & HARRISON Ltd. 22 May, 1967 [24 May, 1966; 10 April, 1967], No. 23688/67. Heading C2U. Novel steroids of formula wherein St is a steroid radical of the androstane or estrane series connected by the 17-position thereof to the lactone ring and R1 is H or C 2-4 aliphatic acyl are prepared by reacting 17- furyl steroids of formula with an organic peracid, any groups or bonds in the radical St which are labile to the organic peracid having previously been protected, to yield a compound of Formula I wherein R1 is H, which upon acylation yields a compound of Formula I wherein R1 is C 2-4 aliphatic acyl (any 3- or 19-hydroxy groups present in the radical St being simultaneously acylated). 17-(3-Furyl)-steroids of Formula II are described as in Specification 1,190,304. In addition the following compounds are disclosed: 17-(3- furyl-1,3,5(10),16-estratetraen-3-ol, 17-(3-furyl)- 5α-androst-16-en-3#-ol and 17-(3furyl)-5#- endrost-16-en-3#-ol (prepared by dehydration of the corresponding 17α(3-furyl)-17#-ols); 17#-(3-furyl)-1,3,5(10)-estratrien-3-ol (prepared by hydrogenation of the corresponding 1,3,5(10), 16-tetraene); and 17#-(3-furyl)-androstane- 3#,5#,14#,19-tetrol (prepared by diisobutyl aluminium hydride reduction of strophanthidol) and the 3,19-diacetate, 3,19-dipropionate and 3,19-dibutyrate thereof. Steroids of Formula I are stated to possess estrogenic, implantation inhibiting, uterotrophic, antigonadotrophic, cardiotonic, antiinflaminatory, androgenic, anabolic, cholesterollowering and mineralocorticoid activities, and may be made up with acceptable carriers or diluents into pharmaceutical compositions suitable for oral or parenteral administration. Reference has been directed by the Comptroller to Specifications 1,081,647 and 1,145,336.